Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 6qc-ICG safety and intraoperative fluorescence study in healthy volunteers and breast cancer surgery patients
NL-OMON59110Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 6QC-ICG in breast cancer and ductal carcinoma in situ (DCIS) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Local tolerability assessment, Pain numeric rating scale and 7 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
6QC-ICG
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NL-OMON59110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59110.